



COMMITMENT LETTER Principles for Responsible Clinical Trial Data Sharing

We, leaders of the pharmaceutical industry, believe that:

- Our commitment to data sharing will enhance research and scientific knowledge, advance patient care and improve public health;
- The dramatic increase in the amount of information that research-based companies will make available to researchers will enhance collaborations in the interest of improved research;
- The interests of patients remain at the heart of everything we do in relation to responsible clinical trial data sharing;
- The industry must be allowed to flourish in order to fulfill its promise in serving patients, past, present and future.

On behalf of the Johnson & Johnson, I hereby confirm our adherence to the Principles for Responsible Clinical Data Sharing launched by PhRMA and EFPIA. We are therefore committed to:

- Establishing policies, procedures or guidelines to reflect the commitments of the Principles;
- Ensuring that relevant employees have received information and training on the Principles; and
- Considering and planning the steps it will take to monitor compliance with the commitments of the Principles on an ongoing basis.

Comp	oany: Johnson & Johnson .,			*********		
Signe	ed on behalf of the company by					
Name	e Duato Fi	rst name	.Joaquin			
Positi <i>Repre</i>	on in the company Worldwi d	le Chairmar pany in rega	ı, Pharmaceı rd of its EFPI	u ticals A memb	ership obliga	 tions
Date	8/7/14	Signature	76	\mathcal{L}	MS	